Skip to main content
Medical Reference · Condition Monograph

Autoimmune Hepatitis

자가면역 간염

Autoimmune hepatitis has been defined as a disease in which an "autoimmune" phenomenon that attacks the liver persists and leads to chronic hepatitis.

History

Autoimmune hepatitis has been defined as a disease in which an "autoimmune" phenomenon that attacks the liver persists and leads to chronic hepatitis. Early on, because it sometimes appeared together with autoimmune diseases such as systemic lupus erythematosus, it was called by names such as "lupoid hepatitis," and other aliases were also attached because of its characteristic features of markedly increased immunoglobulins on blood tests and abundant plasma cells in liver tissue. Over time, the concept became established in the direction of understanding it not as "an accessory symptom of a particular systemic disease" but as an independent spectrum of chronic liver disease.

The biggest change in the history of diagnosis was the introduction of antibody testing and liver biopsy. Because not every case of high liver enzyme levels and jaundice is the same hepatitis, autoantibodies (antinuclear antibody, anti-smooth muscle antibody, anti-liver-kidney microsomal antibody, and others) and immunoglobulin markers came to provide diagnostic clues. In the history of treatment, the key development was the establishment of corticosteroids and azathioprine as standard treatment. As immunosuppressive treatment became widespread, long-term survival improved greatly, and observations also accumulated that "liver fibrosis can be reversed with treatment."

Recent studies conclude that the goal of treatment is moving beyond simply lowering liver values toward reducing corticosteroid side effects, improving long-term quality of life, and adjusting medications to the individual's disease pattern. In addition, as distinguishing it from conditions with a similar appearance, such as drug-induced liver injury and post-vaccination hepatitis, has become important, standardization of diagnosis, treatment, and follow-up is being increasingly emphasized.

Causes

The cause of autoimmune hepatitis cannot be pinned down to a single factor. The core is the phenomenon in which "the immune system mistakes liver cells for foreign invaders and attacks them," and the underlying basis is understood to involve genetic predisposition and environmental factors acting together. Genetic predisposition is often related to groups of genes that determine the direction of immune responses. On top of this, the hypothesis has been discussed that external stimuli such as viral infections, medications, dietary supplements, herbal medicine, and immune stimulation (including vaccination) can act as a "trigger."

In addition, autoimmune hepatitis not infrequently appears together with other autoimmune diseases. It can coexist with thyroiditis, type 1 diabetes, inflammatory bowel disease, celiac disease, and others, suggesting a background of "overall vulnerability in immune regulation." Recent studies have reported a meaningful frequency of coexisting autoimmune diseases in patients with autoimmune hepatitis and emphasize that it is important to check for coexisting diseases at the time of diagnosis.

Summarized from a layperson's point of view, the cause can be described as "a disease in which some stimulus is superimposed on a constitution (heredity), causing the immune system to mistakenly attack the liver, and that state does not switch off but persists for a long time."

Genetic Epidemiology

Autoimmune hepatitis is not determined by a single gene like a typical hereditary disease, but family history and genetic tendencies are known to influence the risk of developing it. In particular, associations with genotypes that regulate immune responses (the human leukocyte antigen family) have been repeatedly discussed in many studies. This genetic background can act in the direction of "the immune system overreacting to certain stimuli, or a reduced ability to switch off reactions that attack one's own body."

However, in clinical practice, genetic testing does not replace diagnosis. This is because the disease may not develop even when the genotype is present and, conversely, it can develop even when the genotype is not clearly present. Genetic information is therefore closer to "a clue for understanding the cause," and actual diagnosis and treatment center on blood tests, biopsy, and observation of the clinical course.

Recent studies conclude that, in addition to genetics, epigenetics (the way switches on genetic information are turned on and off), the gut environment, and the balance of immune cells (an imbalance between regulatory T cells and inflammatory T cells) may be involved in onset and course. In particular, reduced regulatory T cell function and failure of immune signal regulation are mentioned as important factors explaining the self-perpetuating nature of the disease.

General Epidemiology

Autoimmune hepatitis is not a common disease, but reports are tending to increase worldwide, which is interpreted as being influenced in part by improved diagnostic techniques and increased awareness. It is more common in women, and a tendency to show two peaks in particular age groups (adolescence to young adulthood, and middle age) is also known. In reality, however, it can occur at any age. Systematic analyses in recent studies conclude that the incidence and prevalence of autoimmune hepatitis vary greatly by region and study design, but that an overall increasing trend is observed.

A clinically important epidemiological point is that "cirrhosis is not infrequently already present at the time of diagnosis." In other words, the disease can progress even without symptoms, and if it is detected late, a great deal of scarring may already have accumulated. Autoimmune hepatitis must therefore be considered in the differential diagnosis of asymptomatic liver enzyme elevation or chronic hepatitis of unknown cause.

In addition, because coexisting autoimmune diseases are not uncommon, it is also epidemiologically meaningful that in a person with one autoimmune disease, an autoimmune disease of another organ may additionally be found. For early detection, systematic evaluation of liver enzyme abnormalities of unknown cause is important.

Pathogenesis

The core mechanism of autoimmune hepatitis is a breakdown of immune tolerance (the safety mechanism that prevents attacks on one's own body) and a persistent immune response targeting liver cells. In the liver tissue, lymphocytes and plasma cells gather around the portal tracts, interface inflammation appears, and if this inflammation persists, fibrosis progresses and can lead to cirrhosis. Immunologically, T cell-mediated responses are described as central. When inflammatory T cells are activated and the number or function of the regulatory T cells that should suppress them is relatively insufficient, the inflammation does not switch off.

In addition, autoantibodies are useful as "markers" of the disease, but whether the antibodies themselves are the main cause of injury or a product of the immune response is understood in a complex way. The reason environmental factors (infections, medications, and others) are discussed as triggers of onset is that such stimuli can strongly disturb the immune system and promote "the process of turning self-antigens that should normally be ignored into targets of attack."

Recent studies conclude that an imbalance between regulatory T cells and inflammatory T cells and abnormalities in immunosuppressive signals (e.g., the CD39-adenosine pathway) may be involved in the persistence of the disease. Based on this mechanistic understanding, attempts to move from traditional broad immunosuppression toward more targeted treatment are being introduced.

Symptoms

The symptoms of autoimmune hepatitis are very diverse. In some people, only nonspecific symptoms such as fatigue, loss of appetite, nausea, and weight loss persist for a long time, and in some cases it is discovered as elevated liver enzymes at a health checkup without any symptoms. In others, it can begin suddenly like acute hepatitis, with jaundice, right upper abdominal pain, fever, and muscle pain. Systemic symptoms such as joint pain, itching, and rash may also accompany it. In women, menstrual irregularities may be observed as well.

If the disease progresses and cirrhosis develops, it may present with complications such as ascites, leg swelling, vomiting blood or black stools (variceal bleeding), and changes in consciousness (hepatic encephalopathy).

It is important that "liver damage can progress even during periods without symptoms." After diagnosis, inflammatory activity and the risk of fibrosis must be evaluated together regardless of whether symptoms are present. Because of the diversity and nonspecificity of the symptoms, it is very difficult to judge autoimmune hepatitis from symptoms alone.

Signs

There may be no clear findings on physical examination in the early stage. However, if jaundice is present, the skin and sclerae turn yellow, and the liver may be enlarged or tender. In advanced cases, signs of chronic liver disease appear, such as spider angiomas, palmar erythema, ascites, splenomegaly, and muscle loss. On blood tests, elevated liver enzymes (aspartate aminotransferase, alanine aminotransferase) and a tendency toward increased immunoglobulin G are important clues.

On the autoantibody panel, antinuclear antibody, anti-smooth muscle antibody, anti-liver-kidney microsomal antibody, antibodies related to soluble liver antigen, and others may be detected. However, because the antibodies are not always positive, the diagnosis can be made even when antibodies are negative if the clinical and histological findings fit.

Biopsy is central to the evaluation of signs. Findings such as interface hepatitis, plasma cell infiltration, and hepatocyte rosettes support the diagnosis and at the same time allow the degree of fibrosis to be assessed. Recent studies, along with refinement of histological criteria, repeatedly make the point that "in the end, liver histology is what matters for diagnosis."

Screening

Autoimmune hepatitis is not common enough to warrant large-scale population screening. Screening therefore means "in what situations to suspect it and begin testing." First, when unexplained elevation of liver enzymes persists. If common causes such as obesity, alcohol use, medications, viral hepatitis, and biliary disease do not fit or do not sufficiently explain the findings, autoimmune hepatitis must be considered in the differential diagnosis. Second, when abnormal liver values occur in women, people with other autoimmune diseases, or people with findings of hypergammaglobulinemia.

Third, when a patient presents with a pattern of acute hepatitis but viral hepatitis or drug-induced hepatitis is not certain. In this case, rapid diagnosis and treatment can change the prognosis, so autoantibody and immunoglobulin testing and, if necessary, biopsy are actively considered.

Recent studies emphasize that because "early diagnosis" of autoimmune hepatitis can prevent progression to cirrhosis and lower the risk of transplantation, it is important to begin evaluation, under certain criteria, even on the basis of nonspecific symptoms and mild laboratory abnormalities alone.

Diagnosis

The diagnosis is not determined by a single test but is made by combining clinical information, blood tests, and biopsy. The basic structure is "Are there findings consistent with autoimmune hepatitis, and have other causes been reasonably excluded?" Blood tests confirm elevated liver enzymes, increased immunoglobulin G, and positive autoantibodies. The type and titer (strength) of autoantibodies can be reflected in the diagnostic score. However, because there are also antibody-negative forms, the disease is not excluded just because antibodies are absent.

Liver biopsy is close to essential. Biopsy shows the active inflammation and fibrosis stage of autoimmune hepatitis at the same time and also helps differentiate it from steatohepatitis, drug-induced liver injury, and biliary disease. Scoring systems are also used. This is a method that evaluates the likelihood of the diagnosis based on antibodies, immunoglobulin G, histology, exclusion of viral hepatitis, and other factors.

Recent studies conclude that distinguishing drug-induced autoimmune-like hepatitis from true autoimmune hepatitis is clinically important and emphasize an approach that looks at histology and the clinical course (such as whether relapse occurs after treatment) together. Above all, the comprehensive judgment of an experienced care team is most important.

Treatment

The goals of treatment are to quickly calm the inflammation to stop liver damage, to maintain stability over the long term without relapse, and to minimize drug side effects. Standard treatment calms the inflammation with corticosteroids, provides maintenance treatment with azathioprine, and tapers the corticosteroids. If there is no cirrhosis and certain conditions are met, a corticosteroid preparation with fewer side effects may be chosen. The response to treatment is usually good, but not every patient follows the same course.

The duration of treatment is long. It has been repeatedly reported that maintenance treatment is needed for at least several years even after liver values and immunoglobulins normalize, and that relapse is common when medication is stopped. Recent studies emphasize that relapse after stopping treatment is very common, so some patients may need long-term or lifelong maintenance treatment. In addition, treatment is not "medication alone." Corticosteroid-related problems such as osteoporosis, diabetes, weight gain, and infection risk must also be managed.

Recent studies conclude that when azathioprine cannot be used, alternative drugs such as mycophenolate mofetil are widely used, and when the response is poor, drugs such as tacrolimus or even biologic agents are considered on an individual basis. Life planning such as vaccination, infection prevention, and pregnancy planning (the risk of birth defects with some drugs) is also included.

Prognosis

Without treatment, the prognosis can be poor, but with appropriate treatment it is a disease in which long-term survival improves greatly. The key prognostic factors of treatment are "whether complete remission (normalization of liver enzymes and immunoglobulins) is achieved and maintained" and "how far fibrosis had progressed at diagnosis." Recent studies have accumulated evidence that treatment can reverse liver fibrosis or slow its progression. Conversely, if the treatment response is incomplete or relapses are frequent, the risk of cirrhosis may increase.

When cirrhosis develops, general cirrhosis management such as care for portal hypertension, ascites, and variceal bleeding and liver cancer surveillance is needed, and if it progresses to decompensation, liver transplantation is considered. Quality of life is also an important prognostic factor. Recent studies conclude that reduced quality of life is common in patients with autoimmune hepatitis and that long-term corticosteroid treatment, anxiety about an uncertain future, a sense of stigma, and access to medical care and treatment experiences are cited as causes.

To improve the prognosis, treatment that not only controls inflammation but also reduces side effects and addresses long-term quality of life is needed. Early diagnosis, achievement of complete remission, and continuous follow-up are the key factors that determine the prognosis.

Prevention

Autoimmune hepatitis is not a disease that can be prevented with "a single preventive rule," as with infectious diseases. Nevertheless, prevention can realistically be defined as "early detection and prevention of worsening." First, not neglecting liver value abnormalities of unknown cause is the most important secondary prevention. Because autoimmune hepatitis may have no symptoms or nonspecific ones, if abnormalities recur, undergoing autoantibody and immunoglobulin testing and, if necessary, specialist evaluation prevents worsening.

Second, once treatment has begun, preventing relapse is prevention. The key is not to stop medication on your own, to check liver values and immunoglobulins regularly, and to maintain the minimum effective dose while managing side effects. Third, lifestyle management that reduces additional damage to the liver is also important. Because heavy drinking can worsen liver damage, it is safer to avoid it, and caution is needed with unnecessary dietary supplements, herbal medicine, and folk remedies.

Recent studies anticipate that as treatment strategies that lower long-term dependence on corticosteroids and personalized immunomodulatory treatments develop, the scope of "preventing worsening" may widen further. Because obesity and metabolic abnormalities can increase the burden on the liver when they coexist, it is important to manage them together.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.